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Vessel-building mast cells
 
Irradiation instructs mast cells to rebuild blood vessels in oxygen-deprived tissues,
according to Heissig and colleagues on page 739. Low-dose irradiation mobilized adult
and precursor mast cells, which traveled to the ischemic tissue and produced the vessel-
building growth factor VEGF (vascular endothelial growth factor).
Ionizing irradiation has been shown to promote the growth of new blood vessels
through the induction of VEGF and inhibition of endothelial cell death. However, the
primary source of irradiation-induced VEGF and the precise mechanism that triggers its
production were not clear. Mast cells—well-known for their production of histamine
in allergic responses—had been found in tissues undergoing angiogenesis. Mast cells are
also capable of producing VEGF, but whether these cells play a leading or supporting
role in angiogenesis had not been explored.
Heissig et al. now show that mast cells are essential for irradiation-induced vessel
growth in a mouse model of ischemic limb injury. Irradiation-induced cellular dam-
age triggers the production of the degradative enzyme matrix metalloprotease-9
(MMP-9) by largely unknown mechanisms. In this model, local irradiation of the
damaged limb increased MMP-9 production in the ischemic tissue, which liberated
the cytokine Kit ligand (KitL), likely from stromal cells. KitL then attracted VEGF-
producing mast cells into the injured tissue.
At the same time, irradiation mobilized mast cell precursors and endothelial cell
progenitors from the bone marrow, and some of these cells became incorporated
into the growing vessels. Without mast cells, the vessel-building benefits of irradiation
were lost. The authors thus speculate that localized irradiation might improve upon
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current therapies for organ regeneration, which rely on the injection of large numbers of bone
marrow–derived stem cells directly into damaged organs. 
 
CD23 bridges the gap
 
The structure of the low-affinity human immunoglobulin E (IgE) receptor CD23, revealed 
on page 751, accounts for its provocative behavior. Hibbert and colleagues show 
that soluble CD23 (sCD23) can simultaneously bind IgE and the complement 
receptor CD21 on B cells. This binding dexterity helps explain how CD23 and IgE 
cooperate to ramp up the synthesis of more IgE.
The production of IgE—the signature antibody of allergic diseases—is enhanced 
when sCD23 (which is cleaved from the surface of activated B cells by endogenous or 
pathogen-derived proteases) binds to CD21 on other B cells. But it was not clear why 
sCD23 binding to CD21 enhanced the production of IgE but not other antibody 
isotypes, as CD21 is present on all B cells.
The group used NMR spectroscopy to show that sCD23 can bind to both IgE and 
CD21 simultaneously, as their binding sites are nonoverlapping. This dual binding 
capacity allows sCD23 to link IgE and CD21 on the surface of B cells. How this linkage 
triggers IgE production is not yet known, but the process is likely to be similar to one 
initiated by the complement component C3d. C3d, when covalently linked to antigen, 
brings together the B cell receptor (immunoglobulin M) and CD21. This assemblage 
recruits the CD21-associated signaling molecule CD19, which synergizes with the B cell 
receptor to increase activation and proliferation of the cell.
Once IgE levels are high, a trimeric membrane–bound form of CD23 helps turn off IgE 
production, possibly by stabilizing the molecule and preventing its cleavage. The next 
challenge, according to senior author James McDonnell, will be to study CD23-mediated 
IgE regulation in animal models of allergic disease. In the meantime, these data might 
provide a structural basis for the development of novel inhibitors of allergic disease. 
Structure of the CD23 molecule showing the 
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